From Basic To Clinical Practice and Ther Role of Molecular Weigh Heparin
unstable angina is currentyl one of teh leading causes of hospital admission for coronary arterial disease (CAD). It is described as heterogeneous disease refering to a wide spectrum of clinical manifestation from stable angina to myocardial infarction (MI). This angina attac is a clinical manifestation of an imbalece between myocardial oxygendemand and supply. Unstable angina and myocardial infarction are closely related with respect to theri etiology and pathogenesis.
The diagnosis of unstable angina implies recognation of sysmtom of myocardial ischemia like the usual pattern of chest pain. Elevation of plasma level biomarkers including CK-MB, troponin I And Troponin T are sensitive markers to differentiate between unstable angina and non ST Elevation myocardial infarction (NSTEMI). Although many episodes of unstable angina and acute MI are caused by plaque disruption, coronary vasoconstriction plays also an important role as a response of dysfuntional endothelium. In unstable angina, a releatively small erosion of atherosclerotic plaque may lead to reduction in coronary blood flow resulting in exacerbation of angina.
the target of medical management in unstable angina and NSTEMI are control symtoms of myocardial ischemia and prevention of MI and Death as the end poin. the involvement of platetet activation and trombus formation has been well established in patients with unstable angina and has led to teratmen strategies tat include aspirin, antiplatelet aggregation and antithrombitic. in the las Decades, some subcunaeous low moleculer weight (LMWH) ware administrered. pernaarin is a relatively new LMWH available with a high bioavaility and prolonged hal live whose efficacy and safety has already been established. The Prime care study is showing that a uniform dose of parnaparin was adequate for all the patients irrespective ther body weight.
The diagnosis of unstable angina implies recognation of sysmtom of myocardial ischemia like the usual pattern of chest pain. Elevation of plasma level biomarkers including CK-MB, troponin I And Troponin T are sensitive markers to differentiate between unstable angina and non ST Elevation myocardial infarction (NSTEMI). Although many episodes of unstable angina and acute MI are caused by plaque disruption, coronary vasoconstriction plays also an important role as a response of dysfuntional endothelium. In unstable angina, a releatively small erosion of atherosclerotic plaque may lead to reduction in coronary blood flow resulting in exacerbation of angina.
the target of medical management in unstable angina and NSTEMI are control symtoms of myocardial ischemia and prevention of MI and Death as the end poin. the involvement of platetet activation and trombus formation has been well established in patients with unstable angina and has led to teratmen strategies tat include aspirin, antiplatelet aggregation and antithrombitic. in the las Decades, some subcunaeous low moleculer weight (LMWH) ware administrered. pernaarin is a relatively new LMWH available with a high bioavaility and prolonged hal live whose efficacy and safety has already been established. The Prime care study is showing that a uniform dose of parnaparin was adequate for all the patients irrespective ther body weight.
